The PROSIT-BIO Cohort

A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Gionata Fiorino, Natalia Manetti, Alessandro Armuzzi, Ambrogio Orlando, Angela Variola, Stefanos Bonovas, Fabrizio Bossa, Giovanni Maconi, Renata DʼIncà, Paolo Lionetti, Laura Cantoro, Walter Fries, Maria L Annunziata, Francesco Costa, Maria M Terpin, Livia Biancone, Claudio C Cortelezzi, Arnaldo Amato, Sandro Ardizzone, Silvio Danese & 11 others Luisa Guidi, Giulia Rizzuto, Arianna Massella, Angelo Andriulli, Alessandro Massari, Greta Lorenzon, Silvia Ghione, Anna Kohn, Agostino Ventra, Vito Annese, PROSIT-BIO Cohort

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.

METHODS: A prospective, multicenter, cohort study using a structured database.

RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64).

CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.

Original languageEnglish
Pages (from-to)233-243
Number of pages11
JournalInflammatory Bowel Diseases
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 2017

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Observational Studies
Prospective Studies
Ulcerative Colitis
Crohn Disease
Tumor Necrosis Factor-alpha
Safety
Infliximab
Biological Products
Multicenter Studies

Keywords

  • Journal Article

Cite this

The PROSIT-BIO Cohort : A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. / Fiorino, Gionata; Manetti, Natalia; Armuzzi, Alessandro; Orlando, Ambrogio; Variola, Angela; Bonovas, Stefanos; Bossa, Fabrizio; Maconi, Giovanni; DʼIncà, Renata; Lionetti, Paolo; Cantoro, Laura; Fries, Walter; Annunziata, Maria L; Costa, Francesco; Terpin, Maria M; Biancone, Livia; Cortelezzi, Claudio C; Amato, Arnaldo; Ardizzone, Sandro; Danese, Silvio; Guidi, Luisa; Rizzuto, Giulia; Massella, Arianna; Andriulli, Angelo; Massari, Alessandro; Lorenzon, Greta; Ghione, Silvia; Kohn, Anna; Ventra, Agostino; Annese, Vito; PROSIT-BIO Cohort.

In: Inflammatory Bowel Diseases, Vol. 23, No. 2, 02.2017, p. 233-243.

Research output: Contribution to journalArticle

Fiorino, G, Manetti, N, Armuzzi, A, Orlando, A, Variola, A, Bonovas, S, Bossa, F, Maconi, G, DʼIncà, R, Lionetti, P, Cantoro, L, Fries, W, Annunziata, ML, Costa, F, Terpin, MM, Biancone, L, Cortelezzi, CC, Amato, A, Ardizzone, S, Danese, S, Guidi, L, Rizzuto, G, Massella, A, Andriulli, A, Massari, A, Lorenzon, G, Ghione, S, Kohn, A, Ventra, A, Annese, V & PROSIT-BIO Cohort 2017, 'The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar', Inflammatory Bowel Diseases, vol. 23, no. 2, pp. 233-243. https://doi.org/10.1097/MIB.0000000000000995
Fiorino, Gionata ; Manetti, Natalia ; Armuzzi, Alessandro ; Orlando, Ambrogio ; Variola, Angela ; Bonovas, Stefanos ; Bossa, Fabrizio ; Maconi, Giovanni ; DʼIncà, Renata ; Lionetti, Paolo ; Cantoro, Laura ; Fries, Walter ; Annunziata, Maria L ; Costa, Francesco ; Terpin, Maria M ; Biancone, Livia ; Cortelezzi, Claudio C ; Amato, Arnaldo ; Ardizzone, Sandro ; Danese, Silvio ; Guidi, Luisa ; Rizzuto, Giulia ; Massella, Arianna ; Andriulli, Angelo ; Massari, Alessandro ; Lorenzon, Greta ; Ghione, Silvia ; Kohn, Anna ; Ventra, Agostino ; Annese, Vito ; PROSIT-BIO Cohort. / The PROSIT-BIO Cohort : A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. In: Inflammatory Bowel Diseases. 2017 ; Vol. 23, No. 2. pp. 233-243.
@article{68d75a52810b476f93438bf2f2b03497,
title = "The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar",
abstract = "BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.METHODS: A prospective, multicenter, cohort study using a structured database.RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1{\%}), 38 (6.9{\%}) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3{\%}) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9{\%}) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95{\%} CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1{\%}). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7{\%}, 86.4{\%}, and 73.7{\%} for naive, 97.2{\%}, 85.2{\%}, and 62.2{\%} for pre-exposed, and 94.5{\%}, 90.8{\%}, and 78.9{\%} for switch, respectively (log-rank P = 0.64).CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.",
keywords = "Journal Article",
author = "Gionata Fiorino and Natalia Manetti and Alessandro Armuzzi and Ambrogio Orlando and Angela Variola and Stefanos Bonovas and Fabrizio Bossa and Giovanni Maconi and Renata DʼInc{\`a} and Paolo Lionetti and Laura Cantoro and Walter Fries and Annunziata, {Maria L} and Francesco Costa and Terpin, {Maria M} and Livia Biancone and Cortelezzi, {Claudio C} and Arnaldo Amato and Sandro Ardizzone and Silvio Danese and Luisa Guidi and Giulia Rizzuto and Arianna Massella and Angelo Andriulli and Alessandro Massari and Greta Lorenzon and Silvia Ghione and Anna Kohn and Agostino Ventra and Vito Annese and {PROSIT-BIO Cohort}",
year = "2017",
month = "2",
doi = "10.1097/MIB.0000000000000995",
language = "English",
volume = "23",
pages = "233--243",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - The PROSIT-BIO Cohort

T2 - A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

AU - Fiorino, Gionata

AU - Manetti, Natalia

AU - Armuzzi, Alessandro

AU - Orlando, Ambrogio

AU - Variola, Angela

AU - Bonovas, Stefanos

AU - Bossa, Fabrizio

AU - Maconi, Giovanni

AU - DʼIncà, Renata

AU - Lionetti, Paolo

AU - Cantoro, Laura

AU - Fries, Walter

AU - Annunziata, Maria L

AU - Costa, Francesco

AU - Terpin, Maria M

AU - Biancone, Livia

AU - Cortelezzi, Claudio C

AU - Amato, Arnaldo

AU - Ardizzone, Sandro

AU - Danese, Silvio

AU - Guidi, Luisa

AU - Rizzuto, Giulia

AU - Massella, Arianna

AU - Andriulli, Angelo

AU - Massari, Alessandro

AU - Lorenzon, Greta

AU - Ghione, Silvia

AU - Kohn, Anna

AU - Ventra, Agostino

AU - Annese, Vito

AU - PROSIT-BIO Cohort

PY - 2017/2

Y1 - 2017/2

N2 - BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.METHODS: A prospective, multicenter, cohort study using a structured database.RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64).CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.

AB - BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.METHODS: A prospective, multicenter, cohort study using a structured database.RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64).CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.

KW - Journal Article

U2 - 10.1097/MIB.0000000000000995

DO - 10.1097/MIB.0000000000000995

M3 - Article

VL - 23

SP - 233

EP - 243

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -